Your browser doesn't support javascript.
loading
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Ward, Jeffrey P; Berrien-Elliott, Melissa M; Gomez, Felicia; Luo, Jingqin; Becker-Hapak, Michelle; Cashen, Amanda F; Wagner-Johnston, Nina D; Maddocks, Kami; Mosior, Matthew; Foster, Mark; Krysiak, Kilannin; Schmidt, Alina; Skidmore, Zachary L; Desai, Sweta; Watkins, Marcus P; Fischer, Anne; Griffith, Malachi; Griffith, Obi L; Fehniger, Todd A; Bartlett, Nancy L.
Afiliação
  • Ward JP; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Berrien-Elliott MM; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Gomez F; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Luo J; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO.
  • Becker-Hapak M; Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO.
  • Cashen AF; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Wagner-Johnston ND; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Maddocks K; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Mosior M; Division of Hematology, The Ohio State University, Columbus, OH; and.
  • Foster M; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Krysiak K; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO.
  • Schmidt A; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Skidmore ZL; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Desai S; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO.
  • Watkins MP; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
  • Fischer A; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Griffith M; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO.
  • Griffith OL; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Fehniger TA; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO.
  • Bartlett NL; Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
Blood ; 139(13): 1999-2010, 2022 03 31.
Article em En | MEDLINE | ID: mdl-34780623
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Lenalidomida / Brentuximab Vedotin Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Macau
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Lenalidomida / Brentuximab Vedotin Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Macau